Domov › Crohnova choroba › Indiana
Klinické štúdie Crohnova choroba v štáte Indiana
13 štúdií pre Crohnova choroba hľadá účastníkov v zariadeniach v štáte Indiana.
Mestá v štáte Indiana
Oficiálny text štúdie (anglicky)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Indiana University Health University Hospital ( Site 5022), Indianapolis
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284145, New Albany
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07697456Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Indiana University Health University Hospital /ID# 278129, Indianapolis
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- IU Health University Hospital, Indianapolis
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Riley Hospital for Children, Indianapolis
Prebieha náborFáza 3
Vek 3 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06663332Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
Prebieha náborFáza 3
Vek 18 až 70 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05995353A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Riley Childrens Hospital, Indianapolis
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 8. 2026 · NCT05509777Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 6. 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Riley Hospital for Children at Indiana University Health, Indianapolis
Prebieha náborFáza 4
Vek 6 až 17 · Všetky pohlavia · Aktualizované 27. 5. 2026 · NCT05781152Precise Infliximab Exposure and Pharmacodynamic Control
- Riley Hospital for Children, Indianapolis
Prebieha náborFáza 2/3
Vek 6 až 22 · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT05660746Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.